LAVA Therapeutics (LVTX) Short Interest Ratio & Short Volume $1.31 -0.03 (-2.24%) As of 03:50 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LAVA Therapeutics Short Interest DataLAVA Therapeutics (LVTX) has a short interest of 70,500 shares, representing 0.54% of the float (the number of shares available for trading by the public). This marks a -20.79% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.5, indicating that it would take 1.5 days of the average trading volume of 157,580 shares to cover all short positions.Current Short Interest70,500 sharesPrevious Short Interest89,000 sharesChange Vs. Previous Month-20.79%Dollar Volume Sold Short$92.36 thousandShort Interest Ratio1.5 Days to CoverLast Record DateMay 31, 2025Outstanding Shares26,305,000 sharesFloat Size13,020,000 sharesShort Percent of Float0.54%Today's Trading Volume1,848 sharesAverage Trading Volume157,580 sharesToday's Volume Vs. Average1% Short Selling LAVA Therapeutics? Sign up to receive the latest short interest report for LAVA Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLVTX Short Interest Over TimeLVTX Days to Cover Over TimeLVTX Percentage of Float Shorted Over Time LAVA Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/202570,500 shares $92.36 thousand -20.8%0.5%1.5 $1.31 5/15/202589,000 shares $112.14 thousand -16.1%0.7%0.2 $1.26 4/30/2025106,100 shares $132.63 thousand -7.2%0.8%0.3 $1.25 4/15/2025114,300 shares $130.30 thousand -16.6%0.9%0.3 $1.14 3/31/2025137,100 shares $174.12 thousand -28.4%1.1%0.3 $1.27 3/15/2025191,500 shares $248.95 thousand -50.6%1.5%0.5 $1.30 2/28/2025387,300 shares $499.62 thousand +1,443.0%3.0%0.9 $1.29 2/15/202525,100 shares $23.59 thousand -17.2%0.2%0.1 $0.94 1/31/202530,300 shares $29.69 thousand -50.3%0.2%0.3 $0.98 1/15/202561,000 shares $59.17 thousand +34.1%0.4%0.5 $0.97 Get the Latest News and Ratings for LVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/202445,500 shares $43.27 thousand -22.5%0.3%0.4 $0.95 12/15/202458,700 shares $65.16 thousand +178.2%0.4%0.7 $1.11 11/30/202421,100 shares $33.76 thousand -20.1%0.2%0.3 $1.60 11/15/202426,400 shares $41.45 thousand +38.2%0.2%0.6 $1.57 10/31/202419,100 shares $34.57 thousand +695.8%0.1%0.4 $1.81 10/15/20242,400 shares $3.84 thousand -75.5%0.0%0 $1.60 9/30/20249,800 shares $16.27 thousand -69.9%0.1%0.2 $1.66 9/15/202432,500 shares $55.90 thousand -28.4%0.2%0.5 $1.72 8/31/202445,400 shares $79.45 thousand -20.9%0.3%0.7 $1.75 8/15/202457,400 shares $104.47 thousand +36.7%0.4%0.8 $1.82 7/31/202442,000 shares $89.88 thousand -20.6%0.3%0.6 $2.14 7/15/202452,900 shares $95.22 thousand -30.2%0.4%0.7 $1.80 6/30/202475,800 shares $136.44 thousand -5.5%0.5%0.8 $1.80 6/15/202480,200 shares $187.67 thousand -4.8%0.6%0.6 $2.34 5/31/202484,200 shares $190.29 thousand -29.0%0.6%0.4 $2.26 5/15/2024118,500 shares $335.36 thousand -2.3%0.8%0.1 $2.83 4/30/2024121,300 shares $350.56 thousand -37.4%0.9%0.1 $2.89 4/15/2024193,800 shares $567.83 thousand -8.4%1.4%0.1 $2.93 3/31/2024211,600 shares $704.63 thousand -34.3%1.5%0.1 $3.33 3/15/2024322,100 shares $950.20 thousand +476.2%2.3%0.2 $2.95 2/29/202455,900 shares $186.15 thousand +448.0%0.5%0 $3.33 2/15/202410,200 shares $20.60 thousand -88.4%0.1%0 $2.02 1/31/202487,700 shares $146.46 thousand +853.3%0.7%0.1 $1.67 1/15/20249,200 shares $15.36 thousand +15.0%0.1%0.3 $1.67 12/31/20238,000 shares $12.64 thousand -27.3%0.1%0.2 $1.58 12/15/202311,000 shares $17.16 thousand -9.8%0.1%0.4 $1.56 11/30/202312,200 shares $18.49 thousand -28.7%0.1%0.4 $1.52 11/15/202317,100 shares $25.48 thousand -21.6%0.1%0.6 $1.49 10/31/202321,800 shares $25.94 thousand -25.3%0.2%0.7 $1.19 10/15/202329,200 shares $40.59 thousand -20.4%0.3%1.4 $1.39The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 9/30/202336,700 shares $53.95 thousand -3.2%0.3%1.4 $1.47 9/15/202337,900 shares $64.76 thousand -15.0%0.3%1.1 $1.71 8/31/202344,600 shares $78.94 thousand +34.7%0.4%0.7 $1.77 8/15/202333,100 shares $59.58 thousand -32.0%0.3%0.1 $1.80 7/31/202348,700 shares $91.56 thousand -45.2%0.4%0.1 $1.88 7/15/202388,900 shares $176.02 thousand +95.4%0.8%0.1 $1.98 6/30/202345,500 shares $92.37 thousand -50.7%0.5%0.1 $2.03 6/15/202392,300 shares $180.91 thousand +709.7%0.9%0.1 $1.96 5/31/202311,400 shares $21.66 thousand -46.2%0.1%0 $1.90 5/15/202321,200 shares $40.28 thousand +50.4%0.2%0.4 $1.90 4/30/202314,100 shares $21.29 thousand +95.8%0.2%0.2 $1.51 4/15/20237,200 shares $12.82 thousand -30.1%0.1%0.1 $1.78 3/31/202310,300 shares $17.10 thousand -40.1%0.1%0.2 $1.66 3/15/202317,200 shares $29.58 thousand +177.4%0.2%0.3 $1.72 2/28/20236,200 shares $13.89 thousand +40.9%0.1%0.1 $2.24 2/15/20234,400 shares $14.87 thousand -17.0%0.0%0.1 $3.38 1/31/20235,300 shares $19.29 thousand +35.9%0.0%0.2 $3.64 1/15/20233,900 shares $15.02 thousand -38.1%0.0%0.1 $3.85 12/30/20226,300 shares $22.05 thousand +34.0%0.0%0.1 $3.50 12/15/20224,700 shares $18.14 thousand -78.3%0.0%0 $3.86 11/30/202221,700 shares $119.57 thousand +130.9%0.1%0 $5.51 11/15/20229,400 shares $50.20 thousand No Change0.0%0 $5.34 10/31/20229,400 shares $40.70 thousand +213.3%0.0%0 $4.33 10/15/20223,000 shares $11.88 thousand -98.1%0.0%0 $3.96 9/30/2022158,800 shares $725.72 thousand +14,336.4%1.7%0.2 $4.57 9/15/20221,100 shares $2.57 thousand -31.3%0.0%0 $2.34 8/31/20221,600 shares $4.08 thousand -36.0%0.0%0.3 $2.55 8/15/20222,500 shares $6.28 thousand -30.6%0.0%0.3 $2.51 7/31/20223,600 shares $9.36 thousand +71.4%0.0%0.4 $2.60 7/15/20222,100 shares $5.54 thousand +2,000.0%0.0%0.3 $2.64 6/30/2022100 shares $295.00 -85.7%N/A0 $2.95 6/15/2022700 shares $2.00 thousand -30.0%0.0%0.1 $2.85 5/31/20221,000 shares $3 thousand -58.3%0.0%0.1 $3.00 5/15/20222,400 shares $9.53 thousand +200.0%0.0%0.3 $3.97 4/30/2022800 shares $3.26 thousand +14.3%0.0%0.1 $4.07 4/15/2022700 shares $2.96 thousand -41.7%0.0%0.1 $4.23 3/31/20221,200 shares $5.28 thousand +20.0%0.0%0.1 $4.40 3/15/20221,000 shares $4.36 thousand +11.1%0.0%0.1 $4.36 2/28/2022900 shares $4.12 thousand -66.7%0.0%0 $4.58 2/15/20222,700 shares $13.53 thousand -55.0%0.0%0.1 $5.01 1/31/20226,000 shares $33.12 thousand -3.2%0.1%0.3 $5.52 1/15/20226,200 shares $30.94 thousand -55.1%0.1%0.3 $4.99 12/31/202113,800 shares $75.90 thousand -9.8%0.2%0.4 $5.50 12/15/202115,300 shares $78.03 thousand -58.8%0.2%0.4 $5.10 11/30/202137,100 shares $257.47 thousand -28.2%0.4%0.9 $6.94 11/15/202151,700 shares $362.93 thousand -22.4%0.6%1.3 $7.02 10/29/202166,600 shares $507.49 thousand -29.6%0.7%1.4 $7.62 10/15/202194,600 shares $674.50 thousand +26.8%1.0%0.6 $7.13 9/30/202174,600 shares $441.63 thousand +1.2%0.8%0.5 $5.92 9/15/202173,700 shares $467.26 thousand +18.1%0.8%0.5 $6.34Trump’s true trade war strategy (Ad)The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.This is fast becoming the world’s most sought-after resource. 8/31/202162,400 shares $408.72 thousand +2.1%0.7%0.5 $6.55 8/13/202161,100 shares $348.88 thousand No Change0.7%0.5 $5.71 LVTX Short Interest - Frequently Asked Questions What is LAVA Therapeutics' current short interest? Short interest is the volume of LAVA Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 31st, traders have sold 70,500 shares of LVTX short. 0.54% of LAVA Therapeutics' shares are currently sold short. Learn More on LAVA Therapeutics' current short interest. What is a good short interest ratio for LAVA Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LVTX shares currently have a short interest ratio of 2.0. Learn More on LAVA Therapeutics's short interest ratio. What is a good short interest percentage for LAVA Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.54% of LAVA Therapeutics' floating shares are currently sold short. Is LAVA Therapeutics' short interest increasing or decreasing? LAVA Therapeutics saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 70,500 shares, a decrease of 20.8% from the previous total of 89,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is LAVA Therapeutics' float size? LAVA Therapeutics currently has issued a total of 26,305,000 shares. Some of LAVA Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. LAVA Therapeutics currently has a public float of 13,020,000 shares. How does LAVA Therapeutics' short interest compare to its competitors? 0.54% of LAVA Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to LAVA Therapeutics: Black Diamond Therapeutics, Inc. (14.68%), Enanta Pharmaceuticals, Inc. (13.70%), Compugen Ltd. (1.82%), Greenwich LifeSciences, Inc. (16.03%), Protara Therapeutics, Inc. (12.08%), Protalix BioTherapeutics, Inc. (1.39%), RAPT Therapeutics, Inc. (18.41%), Nkarta, Inc. (10.91%), Neumora Therapeutics, Inc. (23.03%), Theratechnologies Inc. (1.28%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short LAVA Therapeutics stock? Short selling LVTX is an investing strategy that aims to generate trading profit from LAVA Therapeutics as its price is falling. LVTX shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against LAVA Therapeutics? A short squeeze for LAVA Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LVTX, which in turn drives the price of the stock up even further. How often is LAVA Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LVTX, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies Black Diamond Therapeutics Short Interest Enanta Pharmaceuticals Short Interest Compugen Short Interest Greenwich LifeSciences Short Interest Protara Therapeutics Short Interest Protalix BioTherapeutics Short Interest RAPT Therapeutics Short Interest Nkarta Short Interest Neumora Therapeutics Short Interest Theratechnologies Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:LVTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
